Market research
BWAY Brainsway Ltd
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 468M
- P/E ratio
- 50.57
- Analyst target
- 19.2667
- Dividend yield
- Not available
- Beta
- 0.1
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 468M
- P/E ratio
- 50.57
- Analyst target
- 19.2667
- Dividend yield
- Not available
- Beta
- 0.1
About
About Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Research context
Brainsway Ltd appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BWAY discussion.
5 years, 6 months ago
Brainsway Ltd is currently in a long term uptrend where the price is trading 18.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.8.
Brainsway Ltd's total revenue rose by 12.3% to $7M since the same quarter in the previous year.
Its net income has increased by 82.5% to $-406K since the same quarter in the previous year.
Finally, its free cash flow grew by 28.9% to $-1M since the same quarter in the previous year.
Based on the above factors, Brainsway Ltd gets an overall score of 5/5.